SPP1 and colitis: Similarly, antibody-mediated OPN inhibition (clone 103D6 (52), 200 μg, every 48 hours) in an additional colitis model, i.e., IL10ko/ko treated with DSS to expedite disease progression, significantly exaggerated colitis symptoms, promoting severe weight loss, colon shortening, reduced spleen weight, and colitis-related mortality, even at recovery phase (Supplemental Figure 9, F–K).